1. Home
  2. Analysis
  3. Evista
  4. Interstitial-lung-disease

Evista and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Evista (raloxifene hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Evista. It is created by eHealthMe based on reports of 25,442 people who have side effects when taking Evista from the FDA, and is updated regularly.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,841 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

25,442 people reported to have side effects when taking Evista.
Among them, 63 people (0.25%) have Interstitial lung disease.

Could Evista cause Interstitial lung disease?

Among these 63 people:

How long have people been on Evista when they have Interstitial lung disease? *

  • < 1 month: 25.0 %
  • 1 - 6 months: 37.5 %
  • 6 - 12 months: 25.0 %
  • 1 - 2 years: 12.5 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Interstitial lung disease when taking Evista? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Interstitial lung disease when taking Evista? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 10.2 %
  • 60+: 89.8 %

What are other drugs people take besides Evista? *

  1. Amlodipine: 8 people, 12.70%
  2. Mobic: 7 people, 11.11%
  3. Enbrel: 7 people, 11.11%
  4. Lipitor: 6 people, 9.52%
  5. Nexium: 5 people, 7.94%
  6. Remicade: 5 people, 7.94%
  7. Prednisolone: 5 people, 7.94%
  8. Aspirin: 5 people, 7.94%
  9. Prednisone: 4 people, 6.35%
  10. Omega-3 Marine Triglycerides: 4 people, 6.35%

What are other side effects people have besides Interstitial lung disease? *

  1. Pneumonia: 10 people, 15.87%
  2. Diarrhea: 9 people, 14.29%
  3. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 8 people, 12.70%
  4. Dyspnea (difficult or laboured breathing): 8 people, 12.70%
  5. Fatigue (feeling of tiredness): 7 people, 11.11%
  6. Weight Decreased: 7 people, 11.11%
  7. Nausea And Vomiting: 7 people, 11.11%
  8. Fever: 7 people, 11.11%
  9. Broken Bone: 6 people, 9.52%
  10. Fall: 6 people, 9.52%

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 11 people, 17.46%
  2. High Blood Pressure: 10 people, 15.87%
  3. Insomnia (sleeplessness): 3 people, 4.76%
  4. Pain: 3 people, 4.76%
  5. Gastritis (inflammation of stomach): 3 people, 4.76%
  6. Constipation: 3 people, 4.76%
  7. Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 3.17%
  8. Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 3.17%
  9. Ovarian Cancer Stage Iii: 2 people, 3.17%
  10. Hepatocellular Carcinoma (liver cancer): 2 people, 3.17%

* Approximation only. Some reports may have incomplete information.

Do you take Evista and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Evista:

Interstitial lung disease treatments and more:

How severe was Interstitial lung disease and when was it recovered:

Expand to all the drugs that have ingredients of raloxifene hydrochloride:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Evista:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Browse all the conditions that are associated with Interstitial lung disease:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride (the active ingredients of Evista) and Evista (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.